3rd Edition of Preventive Medicine World Conference 2027

Abstract

Background: In preventive oncology, early identification of genomic markers is critical to preventing Colorectal Carcinoma (CRC) recurrence and metastasis. Cancer Stem Cells (CSCs) drive therapeutic resistance, yet traditional secondary prevention strategies often overlook their molecular signatures. This genomic report evaluates the molecular pathways (Wnt/beta-catenin and Notch) used by CSCs to evade immune surveillance, aims to demonstrate how early screening can predict resistance, and investigates targeted immunotherapeutic strategies to mitigate long-term oncological risks.

Methodology: A high-throughput screening and systematic review of clinical literature were conducted, focusing on the genomic expression profiles of CD133 and CD44 biomarkers in colorectal CSCs. Data from clinical trials evaluating interactions between these genomic variants and the early-stage tumor microenvironment were synthesized to assess prevention efficacy.

Results & Key Findings: The molecular evaluation revealed that colorectal CSCs actively suppress local T-cellmediated immunity by upregulating PD-L1 expression via altered signaling cascades. Specific genomic variants of CD44 correlated strongly with accelerated metastatic progression. However, early targeted genomic interventions utilizing engineered bispecific T-cell engagers (BiTEs) successfully disrupted these protective niches. Integrating immune checkpoint inhibitors with genomic pathway blockers enhanced tumor mass reduction by over 47% in preclinical models, establishing a robust secondary prevention pathway.

Conclusion: Transitioning from reactive cytotoxic therapies to proactive, genomic-driven preventive oncology is vital for eradicating colorectal CSCs. Implementing systematic molecular screening into early clinical management protocols provides a definitive framework for preventing tumor recurrence and significantly improving patient survival outcomes.